Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + linagliptin (Korea Arlico Pharm)
- Development stage
- Unknown
- Lead developer
- Korea Arlico Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALC-2212 is an incrementally modified drug (IMD) being developed by Korea Arlico Pharm. It is a fixed-dose combination of **empagliflozin**, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and **linagliptin**, a dipeptidyl peptidase-4 (DPP-4) inhibitor. The drug is intended for the treatment of type 2 diabetes mellitus, aiming to provide synergistic glycemic control by targeting two distinct pathways of glucose regulation: increasing urinary glucose excretion and enhancing the incretin effect. As an IMD in the South Korean regulatory framework, it represents a new combination of previously approved active ingredients. It is currently in clinical development, with Phase 1 trials initiated to evaluate its pharmacokinetic profile and safety compared to the individual components.
- Other names
- empagliflozin/linagliptin
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on empagliflozin + linagliptin (Korea Arlico Pharm).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + linagliptin (Korea Arlico Pharm).